ADMA stock forecast, quote, news & analysis
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more
Why ADMA Biologics (ADMA) Stock Is Up +23% in the Last 30 Days
Key Takeaways
- ADMA Biologics shares have risen roughly 23% over the past 30 days, advancing from about $9.11 to approximately $11.23 as the stock rebounded from a mid-September pullback.
- Over the last quarter, the stock has climbed about 34%, though it remains well below its 52-week high after a volatile first half of the year.
- The advance has been supported by continued ASCENIV demand momentum, a reiterated fiscal 2026 revenue outlook, and new peer-reviewed data on the company's optimized manufacturing process.
- Ongoing litigation and governance concerns, together with a reset in medium-term guidance earlier in the year, remain the primary counterweights for investors.
ADMA Biologics (ADMA) Company Overview and Market Position
ADMA Biologics, Inc. is a U.S.-based, end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty plasma-derived biologics for immunodeficient patients and others at risk for certain infectious diseases. The company markets three FDA-approved products: ASCENIV, an intravenous immune globulin (IVIG) indicated for primary humoral immunodeficiency; BIVIGAM, another IVIG for primary immunodeficiency; and Nabi-HB, a hepatitis B immune globulin. ADMA is vertically integrated, operating FDA-licensed plasma collection centers through its ADMA BioCenters subsidiary and manufacturing its products at a plasma fractionation facility in Boca Raton, Florida. The company was the first to receive FDA approval for an innovative yield-enhancement production process that generates roughly 20% more finished immune globulin from the same starting plasma, a key driver of its margin expansion story. Investors follow ADMA closely for its ASCENIV growth trajectory, its capital-efficient manufacturing model, and its pipeline, led by SG-001, a preclinical hyperimmune globulin targeting Streptococcus pneumoniae infections.
ADMA Biologics (ADMA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ADMA shares have gained approximately 23%, moving from about $9.11 in mid-September to roughly $11.23 at the most recent session. The path was not linear: the stock dipped to about $8.61 in mid-September before recovering and breaking back above the $10 level late in the month, then consolidating in the low-$10 range before pushing toward $11 in October.
The broader quarterly picture shows a stronger move. Over the last three months, the stock has climbed roughly 34%, from the low-$8 range in mid-to-late July to the current low-$11 range. Despite this rebound, ADMA remains well below its 52-week high, reflecting a difficult earlier stretch in 2026 when the shares declined sharply amid a guidance reset and litigation-related concerns.
What Drove ADMA Stock Price in the Last 30 Days
The recent 30-day advance reflects a recovery from the mid-September low, with the stock trading above its 20-day moving average for much of the period. Several verified factors have supported the move. Continued demand momentum for ASCENIV, the company's lead product, has reinforced confidence in its commercial execution, and management reiterated its fiscal 2026 revenue outlook of $530 million to $560 million with adjusted EBITDA of $265 million to $300 million. In October, the company also announced a peer-reviewed publication highlighting new data from its optimized, proprietary IVIG manufacturing process, demonstrating effective removal of procoagulant impurities while maintaining immunoglobulin quality and increasing IgG yield. On the sentiment front, Wall Street's consensus rating remains a "Buy," with an average 12-month price target near $17. These positives have been partially offset by ongoing legal scrutiny, including a securities class action alleging revenue-related misstatements and a separate board-level fiduciary duty investigation, which have tempered the rally.
What Drove ADMA Stock Performance Over the Last Quarter
The quarterly trend is best understood in the context of ADMA's broader 2026 narrative. Earlier in the year, the stock declined sharply from its highs as the company reset its medium-term revenue guidance, reported slower top-line growth, and faced litigation overhang. The second-quarter results, reported in early August, showed revenue of about $124.4 million, up roughly 2% year over year, alongside in-line revenue and a modest earnings-per-share miss versus consensus. Against that backdrop, the last-quarter recovery has been driven by fundamentals rather than a single catalyst: scaling of the FDA-approved yield-enhancement process, which supports margin expansion; a shift to a more capital-efficient plasma sourcing model through long-term supply agreements; and a new distribution agreement with McKesson Specialty for ASCENIV and BIVIGAM. These factors have helped stabilize sentiment and underpin a partial re-rating from the stock's mid-year lows.
Trending AI Robots
Investors tracking stocks like ADMA often turn to data-driven tools to help interpret price action and manage timing. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing artificial intelligence trading bots. While Tickeron offers hundreds of AI-powered bots that trade across thousands of tickers, only the most relevant and highest-performing strategies appear in this section. The bots vary by trading style, holding timeframe, and performance metrics, giving users a range of approaches to explore. The page provides a practical starting point for those interested in how algorithmic strategies are being applied to current market conditions, and visitors are encouraged to review the available bots to see which align with their own research process.
ADMA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape ADMA's stock. The company's next quarterly earnings report, scheduled for early November, will be a focal point, with investors watching ASCENIV utilization, revenue growth, margin progression, and any updates to fiscal 2026 guidance. Progress on the SG-001 pipeline program, including an anticipated pre-IND submission to the FDA by year-end 2026, represents a potential longer-term catalyst. The potential ASCENIV pediatric label expansion also remains a key item to monitor. On the risk side, investors should track developments in the securities class action and related governance investigations, as well as competitive dynamics and pricing pressure within the U.S. immune globulin market. Analyst expectations, which currently reflect a "Buy" consensus with an average price target near $17, and continued execution on the yield-enhancement rollout will also influence sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ADMA's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for ADMA moved out of overbought territory on November 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In 30 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ADMA broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on ADMA as a result. In 74 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on November 05, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in 245 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 210 of 254 cases where ADMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.985) is normal, around the industry mean (3.498). P/E Ratio (17.681) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology